Reckitt Benckiser Group (OTCMKTS:RBGLY - Get Free Report) was downgraded by equities research analysts at Sanford C. Bernstein from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Monday, Zacks.com reports.
RBGLY has been the topic of several other reports. UBS Group raised Reckitt Benckiser Group to a "strong-buy" rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. cut Reckitt Benckiser Group from an "overweight" rating to a "neutral" rating in a research report on Thursday, August 29th. Citigroup upgraded Reckitt Benckiser Group to a "strong-buy" rating in a research report on Tuesday, October 1st. Finally, Barclays raised shares of Reckitt Benckiser Group to a "strong-buy" rating in a report on Friday, October 4th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy".
Read Our Latest Stock Report on Reckitt Benckiser Group
Shares of OTCMKTS RBGLY opened at $12.89 on Monday. Reckitt Benckiser Group has a 12 month low of $10.24 and a 12 month high of $15.03. The company has a 50 day simple moving average of $12.22 and a two-hundred day simple moving average of $11.56. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.47 and a current ratio of 0.69.
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.